Novartis Ag (NVS) EBITDA Margin Growth (3y) (2012 - 2026)
Novartis Ag (NVS) EBITDA Margin Growth (3y) (2012 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 120.00 |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 531.00 |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 3,082.00 |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 842.00 |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | -95.00 |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | -347.00 |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | -15,844.00 |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 20,333.00 |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | -2,411.00 |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn | 471.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 842.00 |
| Jun 30, 2025 | 1,718.00 |
| Dec 31, 2024 | 7,346.00 |
| Jun 30, 2024 | 523.00 |
| Dec 31, 2023 | -2,377.00 |
| Jun 30, 2023 | 382.00 |
| Mar 31, 2023 | 154.35 Mn |
| Jun 30, 2022 | -520.00 |
| Mar 31, 2022 | 1.32 Bn |
| Dec 31, 2021 | -75,514.00 |
| Sep 30, 2021 | -282,837.00 |
| Jun 30, 2021 | 545.00 |
| Mar 31, 2021 | 498.23 Mn |
| Dec 31, 2020 | 4,370.00 |
| Sep 30, 2020 | 756.33 Mn |
| Jun 30, 2020 | 210.00 |
| Mar 31, 2020 | -76,883.00 |
| Jun 30, 2019 | -92,768.00 |
| Mar 31, 2019 | -18.31 Bn |
| Dec 31, 2018 | 47,032.00 |